Association of Surgical Delay and Overall Survival in Patients With T2 Renal Masses: Implications for Critical Clinical Decision-making During the COVID-19 Pandemic

Abstract

OBJECTIVE To test for an association between surgical delay and overall survival (OS) for patients with T2 renal masses. Many health care systems are balancing resources to manage the current COVID-19 pandemic, which may result in surgical delay for patients with large renal masses. METHODS Using Cox proportional hazard models, we analyzed data from the National Cancer Database for patients undergoing extirpative surgery for clinical T2N0M0 renal masses between 2004 and 2015. Study outcomes were to assess for an association between surgical delay with OS and pathologic stage. RESULTS We identified 11,848 patients who underwent extirpative surgery for clinical T2 renal masses. Compared with patients undergoing surgery within 2 months of diagnosis, we found worse OS for patients with a surgical delay of 3-4 months (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.00-1.25) or 5-6 months (HR 1.51, 95% CI 1.19-1.91). Considering only healthy patients with Charlson Comorbidity Index = 0, worse OS was associated with surgical delay of 5-6 months (HR 1.68, 95% CI 1.21-2.34, P= .002) but not 3-4 months (HR 1.08, 95% CI 0.93-1.26, P = 309). Pathologic stage (pT or pN) was not associated with surgical delay. CONCLUSION Prolonged surgical delay (5-6 months) for patients with T2 renal tumors appears to have a negative impact on OS while shorter surgical delay (3-4 months) was not associated with worse OS in healthy patients. The data presented in this study may help patients and providers to weigh the risk of surgical delay versus the risk of iatrogenic SARS-CoV-2 exposure during resurgent waves of the COVID-19 pandemic. UROLOGY 00: 1−7, 2020.

Cancer management during the COVID-19 pandemic: Choosing between the devil and the deep blue sea

“…Treatment delay had significant lower overall survival rate per 14 day-delay (HR = 1.06 [1.05-1.07]; (p < 0.001)) ( Grass et al, 2020 ). Ginsburg et al estimated an approximative 10% increase in hazard ratio of all-cause mortality for each month interval between diagnosis and surgery (HR = 1.10 [1.06-1.14]; (p < 0.001)) ( Ginsburg et al, 2020 ). Similarly, a study in Taiwan showed that patients who received treatment between 90 and 180 days after diagnosis had more than 30% risk of death than those who received treatment within 90 days (HR = 1.33; [1.02-1.72]; (p < 0.05)) ( Chen et al, 2019 ).…”

The Impact of the COVID-19 Pandemic on Cancer Care and Health-Related Quality of Life of Non-Hispanic Black/African American, Hispanic/Latina and Non-Hispanic White Women Diagnosed with Breast Cancer in the U.S.: A Mixed-Methods Study Protocol

“…In May 2020, 79% of cancer patients in active treatment experienced some delay in their health care because of COVID-19 [ 56 ]; which may affect long-term survival because of suboptimal or delayed care [ 8 , 13 , 39 , 40 , 41 , 55 , 57 , 58 , 59 ]. Together, these trends can exacerbate pre-existing disparities in cancer morbidity and mortality experiences by Black/African American and Hispanic/Latinx adults [ 47 , 60 , 61 , 62 ].…”

The impact of the coronavirus disease 2019 pandemic on elective urological procedures in Australia

“…Although a delay of 2–3 months are unlikely to affect the oncological outcomes, a further delay has been shown to affect outcomes for some urological malignancies. Surgical delay in MIBC greater than 12 weeks, 5–6 months delay in T2 RCC, delay greater than 120 days for high-grade upper tract urothelial cancer are all associated with a negative impact on the overall survival [ [14] , [15] , [16] ]. This is in contrast to patients’ perspective, where a recent survey of urological patients conducted in Italy showed that majority of patients preferred to delay the surgery and considered the risk of COVID-19 more harmful than delaying surgery [ 17 ].…”